Better treatment options for type B aortic dissection
2/2 IMPRroving Outcomes in Vascular DisEase - Aortic Dissection (IMPROVE-AD)
This project compares adding early minimally invasive aortic repair (TEVAR) to usual medical care versus medical care with watchful waiting for people with uncomplicated type B aortic dissection.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Duke University NIH-funded |
| Lab location | 1 site (Durham, United States) |
| Project ID | NIH-11132820 on NIH RePORTER |
What this research studies
If you have an uncomplicated type B aortic dissection, you could be enrolled at a participating U.S. hospital and randomly assigned to either medicines plus early thoracic endovascular aortic repair (TEVAR) or medicines with regular monitoring and repair only if your condition worsens. The study aims to enroll about 1,100 people and follow them during hospitalization and afterward to track outcomes like survival, complications, and need for later procedures. Care and data collection will be handled by clinical and data coordinating centers at major hospitals working together across the country. The goal is to provide clear guidance on whether early TEVAR leads to better outcomes than a watchful-waiting approach.
Who could benefit from this research
Good fit: Adults diagnosed with uncomplicated type B aortic dissection of the descending aorta who are being managed medically and meet the study's eligibility rules would be ideal candidates.
Not a fit: People with complicated dissections requiring immediate repair, those with type A dissection, or patients with severe comorbidities that make repair unsafe would likely not be eligible or benefit from this comparison.
Why it matters
Potential benefit: If successful, the results could show whether early TEVAR reduces deaths and complications and help doctors choose the best care plan for uncomplicated type B aortic dissection.
How similar studies have performed: Smaller trials and observational studies have suggested benefits of early TEVAR for some patients, but large randomized trials focused on uncomplicated type B dissection have been limited, so this large pragmatic trial is relatively novel.
Where this research is happening
Durham, United States
- Duke University — Durham, United States (Active)
Researchers
- Principal investigator: O'brien, Sean M — Duke University
- Study coordinator: O'brien, Sean M
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.